[EN] HETEROCYCLIC COMPOUNDS AS BTK INHIBITORS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES UTILISÉS COMME INHIBITEURS DE BTK
申请人:BEIJING INNOCARE PHARMA TECH CO LTD
公开号:WO2022037649A1
公开(公告)日:2022-02-24
Disclosed are heterocyclic compounds of formula (I) or their pharmaceutically acceptable salts used as inhibitors of Bruton's tyrosine kinase (BTK) and its C481 mutant. Disclosed also are methods for preparing compounds of formula (I) or their pharmaceutically acceptable salts. Those compounds can be used to treat and/or prevent related diseases mediated by BTK or its C481 mutant, especially cancer and autoimmune diseases.
公开了公式(I)的杂环化合物或其药学上可接受的盐,用作Bruton酪氨酸激酶(BTK)及其C481突变体的抑制剂。还公开了制备公式(I)的化合物或其药学上可接受的盐的方法。这些化合物可用于治疗和/或预防由BTK或其C481突变体介导的相关疾病,特别是癌症和自身免疫疾病。